Michael Zasloff

He later co-founded a company called Enterin, that intended to develop a derivative of squalamine called kenterin as a treatment for Parkinson's disease; the company received its first round of venture funding in 2017.

In 2013 Zasloff co-founded a company called Formula XO that sold haircare products.

Zasloff left Penn in 1992 and joined Magainin full time. He was with the company until its lead product, pexiganan, was rejected by the FDA in 1999 for lack of efficacy compared with the standard of care for diabetic foot ulcers, and he went to Georgetown University's medical school, where he was appointed Dean for Research and Translational Science. In 2011 Zasloff found that squalamine had antiviral activity.

Zasloff stayed at the NIH after he finished his postdoc, and in 1981 he was made the Chief of the Human Genetics Branch of the National Institutes of Child Health and Human Development. In 1986 he discovered magainins, a family of antimicrobial peptides in the skin of the African clawed frog.

Magainin Pharmaceuticals, Inc. was founded in the late 1980s to commercialize the peptides. Zasloff left the NIH at about the same and went to University of Pennsylvania, in part because the NIH policies made it difficult for him to participate in the company. Magainin eventually went public and its name was changed to Genaera. The company attempted to develop squalamine, trodusquemine, and pexiganan (a version of a magainin), but the company closed in 2009 without having brought any products to market.

He did his residency training in pediatrics at the Boston Children's Hospital and a research fellowship at Johns Hopkins University. In 1975 he joined the National Institutes of Health (NIH) as a postdoc.

Michael A. Zasloff (born July 2, 1946) is an American physician, medical researcher, and entrepreneur. Zasloff is primarily known for his work on antimicrobial peptides.